Category: disease
-
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Feb 22, 2025 • 10 minute…
-
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Jan 26, 2025 • 17 minute…
-
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Jan 13, 2025 • 16 minute…
-
Teva jumps sharply on bowel disease drug results
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa The stock price opened 20% higher on Wall Street after the Israeli company announced positive results from the phase 2 clinical trial of Docavitog, which it is developing with Sanofi, to treat ulcerative colitis (UC) and Crohn’s disease (CD).…
-
Sanofi MS drug tolebrutinib misses goal in relapsing disease trials By Reuters
•
By Ludwig Berger (Reuters) – Sanofi Nasdaq:NASDAQ:NASDAQ:MSN’S most advanced multiple sclerosis drug failed to meet the main goal of two late-stage trials to treat recurrent forms of the disease, dimming the prospects for a broad class of drugs. The French drugmaker said on Monday that two phase 3 trials showed…
-
Israeli AI disease models co CytoReason raises $80m
•
Israeli biopharmaceutical decision-making company citorisonTechnologies, which develops AI-powered computational disease models for predictive insights, today announced the completion of an $80 million funding round from OurCrowd, Nvidia, Pfizer, and Thermo Fisher Scientific. Cytorison says it will use the new funds to expand the application of its models in additional indications,…
-
Israeli AI disease models co CytoReason raises $80m
•
Israeli biopharmaceutical decision-making company citorisonTechnologies, which develops AI-powered computational disease models for predictive insights, today announced the completion of an $80 million funding round from OurCrowd, Nvidia, Pfizer, and Thermo Fisher Scientific. Cytorison says it will use the new funds to expand the application of its models in additional indications,…
-
“LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel By Investing.com
•
TOKYO and CAMBRIDGE, Mass., July 12, 2024 – (JCN NewsWire) – Eisai Co., Ltd. (OTC:) and Biogen Co., Ltd. (NASDAQ:) today announced the approval of the beta-amyloid (Aβ)-degrading monoclonal antibody “LEQEMBI” (generic name: lecanemab) in Israel as a treatment for Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in…
-
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters
•
(Reuters) – Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug developer Morphek surged 76% to $56.15 premarket after Lilly’s offer…
-
CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
•
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the ECHO Phase III trial showed AstraZeneca (NASDAQ:)’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival…
-
NMDP BioTherapies To Present Data at ISCT 2024 on the Stability of Infectious Disease Marker Analytes During Donor Qualification for Allogeneic Cell Therapies
•
Article content The study, jointly conducted by researchers from Labor Quade and Johns Hopkins University School of Medicine, analyzed the long-term stability of IDM analytes in non-centrifuged peripheral blood samples to allow for increased flexibility in processing donor samples. The study results indicate that the widespread use of blood processing…